OQS
VRDN icon

Occudo Quantitative Strategies’s Viridian Therapeutics VRDN Stock Holding History

Occudo Quantitative Strategies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,720
Closed -$231K – 1334
2023
Q2 		$231K Buy
+9,720
New +$249K 0.02% 812
2022
Q4 		– Sell
-15,764
Closed -$323K – 1405
2022
Q3 		$323K Buy
+15,764
New +$283K 0.03% 820

Other funds holding VRDN

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Occudo Quantitative Strategies's VRDN Position: Q3 2023 in Review

Occudo Quantitative Strategies sold out of Viridian Therapeutics (VRDN) in Q3 2023, closing a stake of 9,720 shares — an estimated $231K sold.

Occudo Quantitative Strategies first reported a position in VRDN in Q3 2022 and held it in 2 quarters. The position peaked at $323K in Q3 2022. 123 funds tracked by Wall St. Rank hold VRDN as of Q3 2023.

  • Occudo Quantitative Strategies reported no remaining Viridian Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 9,720 Viridian Therapeutics shares in Q3 2023, an estimated $231K.
  • Occudo Quantitative Strategies first reported a position in Viridian Therapeutics in Q3 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Viridian Therapeutics position peaked at $323K in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.